M32 What's New in the Management of Multiple Endocrine Neoplasia Type 2

Program: Meet-the-Professor Sessions
Clinical Session
Sunday, April 3, 2016: 10:00 AM-10:45 AM
Room 257 (BCEC)
Sunday, April 3, 2016: 2:15 PM-3:00 PM
Room 257 (BCEC)
Speaker:
Robert F Gagel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Disclosures:
RFG: Principal Investigator, Astra Zeneca.

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire